Normal view
-
cs.AI, q-bio.NC updates on arXiv.org
-
COMMA: A Communicative Multimodal Multi-Agent Benchmark
arXiv:2410.07553v5 Announce Type: replace Abstract: The rapid advances of multimodal agents built on large foundation models have largely overlooked their potential for language-based communication between agents in collaborative tasks. This oversight presents a critical gap in understanding their effectiveness in real-world deployments, particularly when communicating with humans. Existing agentic benchmarks fail to address key aspects of inter-agent communication and collaboration, particular
-
(Multiomics OR Omics) AND (Lung OR gastric OR Hepatocellular)
-
The emerging role of microbiota in lung cancer: a new perspective on lung cancer development and treatment
Cell Oncol (Dordr). 2025 Aug 26. doi: 10.1007/s13402-025-01103-3. Online ahead of print.ABSTRACTLung cancer remains the leading cause of cancer-related mortality worldwide, with limited treatment efficacy and frequent resistance to conventional therapies. Recent advances have uncovered the critical influence of the human microbiota-complex communities of bacteria, viruses, fungi, and other microorganisms-on lung cancer pathogenesis and therapeutic responses. This review synthesizes current knowl
The emerging role of microbiota in lung cancer: a new perspective on lung cancer development and treatment
Cell Oncol (Dordr). 2025 Aug 26. doi: 10.1007/s13402-025-01103-3. Online ahead of print.
ABSTRACT
Lung cancer remains the leading cause of cancer-related mortality worldwide, with limited treatment efficacy and frequent resistance to conventional therapies. Recent advances have uncovered the critical influence of the human microbiota-complex communities of bacteria, viruses, fungi, and other microorganisms-on lung cancer pathogenesis and therapeutic responses. This review synthesizes current knowledge on the compositional and functional roles of microbiota across multiple body sites, including the gut, lung, tumor microenvironment, circulation, and oral cavity, highlighting their contributions to tumor initiation, progression, metastasis, and immune regulation. We emphasize the bidirectional communication between microbial metabolites and host immune pathways, particularly the gut-lung axis, which modulates systemic and local antitumor immunity. Importantly, microbiota composition has been linked to differential responses and toxicities in chemotherapy, radiotherapy, targeted therapy, and immune checkpoint blockade. Microbiota-targeted interventions, such as probiotics, fecal microbiota transplantation, and selective antibiotics, show promising potential to enhance treatment efficacy and mitigate adverse effects. However, challenges remain in clinical translation due to interindividual microbiome variability, mechanistic complexities, and limited longitudinal data. Future research integrating multi-omics, microbial functional profiling, and controlled clinical trials is essential to harness the microbiome as a precision medicine tool in lung cancer management. This review provides a comprehensive overview of the emerging role of microbiota in lung cancer development and therapy, offering new perspectives for innovative therapeutic strategies.
PMID:40856929 | DOI:10.1007/s13402-025-01103-3
-
Most Recent Articles: Clinical Epigenetics
-
Genetic, DNA methylation, and immune profile discrepancies between early-stage single primary lung cancer and synchronous multiple primary lung cancer
To explore the possible carcinogenesis and help better diagnose and treat patients with synchronous multiple primary lung cancers (sMPLC), we systematically investigated the genetic and DNA methylation profile...